Introduction: Ovarian cancer is the fourth most prevalent cancer
among women and the seventh most common cancer overall.
Every year, an estimated 200,000 cases and 125,000 deaths related to ovarian
cancer are reported around the world. It is most common in high-resource
countries, with an incidence rate of 9.3 per 100,000 women.Ovarian
cancer is detected at an advanced stage in about 70% of instances, and only 30%
of women with such cancers live for more than 5 years. Although only around 20%
of ovarian cancers are limited to the ovaries at diagnosis, patients with
localized disease have a 5-year survival rate of more than 90%.Peritonectomy
is a crucial part of the surgical treatment for ovarian cancer. Visual
inspection and palpation are not reliable methods for determining the extent of
tumour involvement. The majority of gynecologic oncologists are suspicious
about the benefits of a full peritonectomy, concerned about the benefits and
hazards. They believe that the tumor’s fundamental biology, not surgical
aggressiveness, dictates the tumor’s resectability. The aim of this work was
primarily to compare the differences between total peritoneal gutter removal
and random peritoneal biopsy in cases of early ovarian cancer. A secondary aim
of this work is to show ability of total peritoneal gutter removal in relation
to that of random peritoneal biopsy to detect positivity of metastasis in the
histopathological specimens. Patients and Methods: This prospective
cohort study was conducted on 130 patients with early ovarian cancer in
El-Shatby hospital, Faculty of Medicine, Alexandria University. For each
patient, we took random and total peritoneal biopsy and compared between them
regarding technique, timing, post-operative complications, and
histopathological results. Inclusion criteria:all age group, suspected
ovarian cancer using IOTA score, absence of nodules in the peritoneal gutter
using CT and any case that needs staging laparotomy for ovarian cancer.Exclusion
criteria:
References
[1]
Kurman, R.J., Carcangiu, M.L., Young, R.H. and Herrington, C.S. (2014) WHO Classification of Tumours of Female Reproductive Organs. 4th Edition, IARC Publications, Lyon.
[2]
Fleming, G.F., Seidman, J. and Lengyel, E. (2013) Epithelial Ovarian Cancer. In: Barakat, R.R., Markman, M., Randall, M.E., Eds., Principles and Practice of Gynecologic Oncology, 6th Edition, Lippincott Williams & Wilkins, Philadelphia, 757-847.
[3]
Whitney, C.W. and Spirtos, N. (2009) Gynecologic Oncology Group Surgical Procedures Manual. Gynecologic Oncology Group, Philadelphia.
[4]
Bristow, R.E., Chang, J., Ziogas, A., Campos, B., Chavez, L.R. and Anton-Culver, H. (2015) Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival. Journal of the American College of Surgeons, 220, 940-950. https://doi.org/10.1016/j.jamcollsurg.2015.01.056
[5]
Lalwani, N., Shanbhogue, A.K., Vikram, R., Nagar, A., Jagirdar, J. and Prasad, S.R. (2010) Current Update on Borderline Ovarian Neoplasms. AJR American Journal of Roentgenology, 194, 330-336. https://doi.org/10.2214/AJR.09.3936
[6]
Morice, P., Uzan, C., Fauvet, R., Gouy, S., Duvillard, P. and Darai, E. (2012) Borderline Ovarian Tumour: Pathological Diagnostic Dilemma and Risk Factors for Invasive or Lethal Recurrence. The Lancet Oncology, 13, e103-e115.
https://doi.org/10.1016/S1470-2045(11)70288-1
[7]
Silva, E.G., Gershenson, D.M., Malpica, A. and Deavers, M. (2006) The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms with Noninvasive Implants Is Time Dependent. The American Journal of Surgical Pathology, 30, 1367-1371. https://doi.org/10.1097/01.pas.0000213294.81154.95
Yancik, R. and Ries, L.G. (1989) Caring for Elderly Cancer Patients. Quality Assurance Considerations. Cancer, 64, 335-341.
https://doi.org/10.1002/1097-0142(19890701)64:1+<335::AID-CNCR2820641335>3.0.CO;2-4
[10]
Van Calster, B., Van Hoorde, K., Froyman, W., et al. (2015) Practical Guidance for Applying the ADNEX Model from the IOTA Group to Discriminate between Different Subtypes of Adnexal Tumors. Facts Views Vis Obgyn, 7, 32-41.
[11]
Zanon, C., Clara, R., Chiappino, I., et al. (2004) Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer. World Journal of Surgery, 28, 1040-1045.
https://doi.org/10.1007/s00268-004-7461-x
[12]
Querleu, D., Planchamp, F., Chiva, L., et al. (2017) European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. International Journal of Gynecological Cancer, 27, 1534-1542.
https://doi.org/10.1097/IGC.0000000000001041
[13]
Bhatt, A., Kammar, P., Sinukumar, S., et al. (2021) Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer after Neoadjuvant Chemotherapy: Results from a Prospective Multi-Centric Study. Annals of Surgical Oncology, 28, 1118-1129.
https://doi.org/10.1245/s10434-020-08918-4